Stryker takes $400m stake in CMR Surgical with buyout option
Stryker has agreed a strategic alliance with CMR Surgical that includes a roughly $400 million (£300 million) preferred equity investment, an exclusive option to acquire the remaining equity of the Cambridge-based company at a future date, and a commercial agreement making Stryker the sole US sales agent for CMR's Versius soft-tissue robotic surgery portfolio.
The deal, announced on 12 October 2026 and subject to regulatory clearances and customary closing conditions, hands CMR Surgical a substantial capital injection to fund further product development and international expansion, while giving Stryker a structured, staged route into one of medtech's fastest-moving segments. Andy Pierce, Group President, Medsurg and Neurotechnology at Stryker, will join the CMR Surgical board of directors under the terms of the agreement.
The deal
Under the arrangement, CMR Surgical retains responsibility for portfolio development and commercialisation outside the United States, while Stryker takes over as exclusive US sales agent. Stryker described the acquisition option as providing the opportunity to purchase 100% of CMR Surgical's outstanding equity in the future, though no timeline or price was disclosed.
CMR Surgical chief executive Massimiliano Colella said the alliance was "a significant milestone" and "a strong endorsement of the technology, clinical experience and global business we have built." The company, founded in 2014 and headquartered in Cambridge, produces the Versius platform, a modular second-generation robotic system designed for soft-tissue procedures across hospital operating theatres and ambulatory surgical centres.
Stryker's Pierce framed the move as a considered entry into soft-tissue robotics, a segment he described as "a high-growth adjacency and a natural extension of Stryker's strengths in endoscopy, visualisation and enabling technologies." He added that Stryker had evaluated the market for several years before committing.
Market context
The agreement positions Stryker as a more direct competitor in robotic-assisted surgery, a space dominated by Intuitive Surgical's da Vinci system, which holds an entrenched position in soft-tissue and laparoscopic procedures across the US and internationally. A number of challengers have sought to erode that dominance, and CMR Surgical has pursued a modular, scalable architecture specifically aimed at reducing the capital and workflow barriers that have slowed robotic adoption beyond large academic medical centres.
Stryker's entry via a minority stake with an acquisition option rather than an outright purchase reflects a pattern becoming more common in medtech: the acquirer preserves financial flexibility while the target retains operational independence during a period of commercial scaling. For CMR Surgical, the US market has long been the most significant gap in its global footprint, given the regulatory and distribution complexity of breaking into that environment without an established commercial partner.
The robotic surgery sector has attracted sustained investor interest, with demand for minimally invasive procedures continuing to grow across general surgery, gynaecology and urology. Health systems are under pressure to expand robotic programmes while managing capital expenditure, which is the specific operational challenge that CMR Surgical's modular Versius design targets.
Regulatory filings associated with the closing process will be closely watched, as will any update on the terms or timeline attached to Stryker's acquisition option, which represents the most consequential element of the deal for long-term observers of both companies.